PURPOSE: Immunosuppressive therapy after liver transplantation for hepatocellular carcinoma (HCC) is one of the major contributory factors for HCC recurrence and metastasis. Sirolimus, a potent immunosuppressant, has been reported to be an effective inhibitor in a variety of tumors. The present study is designed to explore whether sirolimus could block the growth and metastatic progression of HCC. METHODS: MHCC97H cells were used as targets to explore the effect of sirolimus on cell cycle progression, apoptosis, proliferation, and its antiangiogenic mechanism. LCI-D20, a highly metastatic model of human HCC in nude mice, was also used as the model tumor to explore the effect of sirolimus on tumor growth and metastatic progression. RESULTS: In vitro, sirolimus induced cell cycle arrest at the G1 checkpoint and blocked proliferation of MHCC97H cells but did not induce apoptosis. In vivo, sirolimus prevented tumor growth and metastatic progression in LCI-D20. Intratumoral microvessel density and circulating levels of VEGF in tumor-bearing mice were also significantly reduced in sirolimus treatment group. Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia. CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus may be useful for clinical application in patients who received a liver transplant for HCC.
PURPOSE: Immunosuppressive therapy after liver transplantation for hepatocellular carcinoma (HCC) is one of the major contributory factors for HCC recurrence and metastasis. Sirolimus, a potent immunosuppressant, has been reported to be an effective inhibitor in a variety of tumors. The present study is designed to explore whether sirolimus could block the growth and metastatic progression of HCC. METHODS: MHCC97H cells were used as targets to explore the effect of sirolimus on cell cycle progression, apoptosis, proliferation, and its antiangiogenic mechanism. LCI-D20, a highly metastatic model of human HCC in nude mice, was also used as the model tumor to explore the effect of sirolimus on tumor growth and metastatic progression. RESULTS: In vitro, sirolimus induced cell cycle arrest at the G1 checkpoint and blocked proliferation of MHCC97H cells but did not induce apoptosis. In vivo, sirolimus prevented tumor growth and metastatic progression in LCI-D20. Intratumoral microvessel density and circulating levels of VEGF in tumor-bearing mice were also significantly reduced in sirolimus treatment group. Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells. Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia. CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression. Sirolimus may be useful for clinical application in patients who received a liver transplant for HCC.
Authors: Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler Journal: Nat Med Date: 2002-02 Impact factor: 53.440
Authors: Stephen Chan; Max E Scheulen; Stephen Johnston; Klaus Mross; Fatima Cardoso; Christian Dittrich; Wolfgang Eiermann; Dagmar Hess; Rudolph Morant; Vladimir Semiglazov; Markus Borner; Marc Salzberg; Valerijus Ostapenko; Hans-Joachim Illiger; Dirk Behringer; Nathalie Bardy-Bouxin; Joseph Boni; Steven Kong; Maria Cincotta; Laurence Moore Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: Bernard Burke; Ngai Tang; Kevin P Corke; Dean Tazzyman; Kurosh Ameri; Michael Wells; Claire E Lewis Journal: J Pathol Date: 2002-02 Impact factor: 7.996
Authors: Georg Breier; Sabine Blum; Janos Peli; Marcel Groot; Carola Wild; Werner Risau; Ernst Reichmann Journal: Int J Cancer Date: 2002-01-10 Impact factor: 7.396
Authors: R K Jain; N Safabakhsh; A Sckell; Y Chen; P Jiang; L Benjamin; F Yuan; E Keshet Journal: Proc Natl Acad Sci U S A Date: 1998-09-01 Impact factor: 11.205
Authors: Norman M Kneteman; José Oberholzer; Mohammed Al Saghier; Glenda A Meeberg; Maurice Blitz; Mang M Ma; Winnie W S Wong; Klaus Gutfreund; Andrew L Mason; Larry D Jewell; A M James Shapiro; Vincent G Bain; David L Bigam Journal: Liver Transpl Date: 2004-10 Impact factor: 5.799
Authors: T Wang; H S Hu; Y X Feng; J Shi; N Li; W X Guo; J Xue; D Xie; S R Liu; M C Wu; S Q Cheng Journal: Br J Cancer Date: 2010-05-11 Impact factor: 7.640
Authors: R K Kelley; H S Nimeiri; P N Munster; M T Vergo; Y Huang; C-M Li; J Hwang; M F Mulcahy; B M Yeh; P Kuhn; M S Luttgen; J A Grabowsky; L Stucky-Marshall; W M Korn; A H Ko; E K Bergsland; A B Benson; A P Venook Journal: Ann Oncol Date: 2013-03-21 Impact factor: 32.976
Authors: Rosa H Jimenez; Joan M Boylan; Ju-Seog Lee; Mirko Francesconi; Gastone Castellani; Jennifer A Sanders; Philip A Gruppuso Journal: PLoS One Date: 2009-10-09 Impact factor: 3.240